Studies have shown that thyroid carcinomas bearing BRAF mutations are less sensitive to BRAF inhibitors and can develop primary or acquired resistance due to mutational events or the activation of alternative pathways [113]. This evidence concerns the gene BRAF and thyroid gland carcinoma.